- Samsung Biologics to embed PSCI principles into business
practices for responsible value chain management
- Supplier Partnership reaffirms company's commitment to
decarbonize and build resilient supply chains
INCHEON, South Korea, Aug. 6, 2024
/PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global
contract development and manufacturing organization (CDMO),
announced today that the company has joined the Pharmaceutical
Supply Chain Initiative (PSCI) as a Supplier Partner.
Samsung Biologics is the first Korean CDMO to participate in the
PSCI, a group of pharmaceutical and healthcare companies that share
a common vision of excellence in safety, environmental, and social
outcomes across the global healthcare value chain. Samsung
Biologics will commit to PSCI principles that address five areas of
responsible business practice – ethics, labor, health & safety,
environment, and management systems.
Samsung Biologics expects the partnership to help further
advance the company's steadfast dedication to sustainable growth
and strengthen its Environmental, Social, and Governance (ESG)
management. As part of its efforts to decarbonize and build more
resilient supply chains, Samsung Biologics has been engaging
suppliers as champion of the Supply Chains Working Group within the
Sustainable Market Initiative's Health Systems Task Force.
"We are pleased to join the PSCI and hope to actively support
collective actions to improve supply chain management," said
John Rim, CEO and President of
Samsung Biologics. "As part of our commitment to deliver safe,
high-quality biomedicines, we will incorporate PSCI principles into
our business practices and promote responsible conduct among our
suppliers to drive sustainable change across the supply chain,
contributing to a healthier future."
About Samsung Biologics Co., Ltd.
Samsung Biologics (KRX: 207940.KS) is a fully integrated,
end-to-end CDMO service provider, offering seamless development and
manufacturing solutions from cell line development to final aseptic
fill/finish as well as laboratory testing support for the
biopharmaceutical products we manufacture. Our state-of-the-art
facilities are CGMP compliant with bioreactors ranging from small
to large scales to serve varying client needs. To maximize our
operational efficiency and expand our capabilities in response to
growing biomanufacturing demand, Samsung Biologics completed
Bio Campus I with Plant 4, offering
a combined 604 KL total capacity, and launched Bio Campus II with the construction of Plant 5,
which will be operational in April
2025, adding 180 KL biomanufacturing capacity. Additionally,
Samsung Biologics America enables the company to work in closer
proximity to clients based in the U.S. and Europe. We continue to upgrade our
capabilities to accommodate our clients by investing in
technologies such as an antibody-drug conjugate (ADC) facility, a
dedicated mRNA manufacturing facility, and additional aseptic
filling capacity. As a sustainable CDMO partner of choice, we are
committed to on-time, in-full delivery of the products we
manufacture with our flexible manufacturing solutions, operational
excellence, and proven expertise.
Samsung Biologics Media Contact
Claire Kim, Head of Marketing Communications
cair.kim@samsung.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/samsung-biologics-joins-the-pharmaceutical-supply-chain-initiative-as-supplier-partner-302214949.html
SOURCE Samsung Biologics